Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

ConclusionsWe confirmed that gBRCA1/2 deficiency and advanced stage are independent risk factors for development of carboplatin hypersensitivity in ovarian cancer patients. Our study also shows improved OS in hypersensitive patients receiving CD compared to non-hypersensitive patients, independent of gBRCA1/2.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research